<unk>  has been approved by the FDA for the acute treatment of adults with schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. In Australia<unk> 's approved (and also listed on the PBS) indications include the following: * Schizophrenia * Treatment, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder * Maintenance treatment, as monotherapy, of bipolar I disorder In the European Union and the United Kingdom,<unk>  is only licensed for use as a treatment for acute mania in bipolar I disorder. Absorbed readily if administered sublingually,<unk>  is poorly absorbed when swallowed. Schizophrenia=== A Cochrane systematic review found that while<unk>  has some preliminary evidence that it improves positive, negative, and depressive symptoms, it does not have enough research to merit a certain recommendation of<unk>  for the treatment of schizophrenia. Acute mania As for its efficacy in the treatment of acute mania, a recent meta-analysis showed that it produces comparatively small improvements in manic symptoms in patients with acute mania and mixed episodes than most other antipsychotic drugs (with the exception of ziprasidone) such as risperidone and olanzapine. Drop-out rates (in clinical trials) were also unusually high with<unk> . According to a post-hoc analysis of two 3-week clinical trials it may possess some antidepressant effects in patients with acute mania or mixed episodes.
Asenapine
Sertraline
Aripiprazole
Mirtazapine
Loxapine
Amoxapine
Perlapine
Trimipramine